Effective Strategies to Manage Hyperglycemia When Treating with PI3K and AKT Inhibitors

Program Description

Effective management and prevention of hyperglycemia are critical for patients with breast cancer undergoing treatment with PI3K and AKT inhibitors. This webinar will provide oncology pharmacists with proactive strategies to mitigate these risks and identify key risk factors that predispose patients to this adverse effect. A key focus of the program will be on the challenges and considerations in selecting appropriate antihyperglycemic therapies, such as metformin, sodium glucose co-transporter 2 (SGLT2) inhibitors, and other lifestyle interventions. Given that the PI3K/AKT pathway is a central target for both cancer and glucose metabolism, certain antidiabetes medications may present unique considerations and interactions with anticancer drugs that oncology pharmacists must advise upon within the interprofessional health care team. Throughout the webinar, opportunities for oncology pharmacists to engage in interventions in both the preventative and management settings, including the development of monitoring protocols to ensure patients with breast cancer can remain on their therapies with minimal metabolic complications, will be emphasized.

Target Audience: Oncology Pharmacist

Type of Activity: Application
Release date: November 7, 2025
Expiration date: November 7, 2026
Learner level: Intermediate
Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Identify key risk factors for hyperglycemia in patients receiving PI3K and AKT inhibitors
• Explore evidence-based prevention strategies for hyperglycemia, including pharmacologic options and lifestyle interventions
• Express the challenges and considerations in selecting antihyperglycemic therapies for patients treated with PI3K or AKT inhibitors
• Show how oncology pharmacists can lead and support proactive interventions in both prevention and management settings to improve outcomes for patients at risk of or experiencing treatment-induced hyperglycemia